Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2004

View Archived Issues

Genistein reported to reduce hot flushes in postmenopausal women

Pergolide improves erectile dysfunction in male patients with advanced PD

FL-61, a potent new urotensin-II agonist, under early evaluation at Acadia

Combio synthesizes potent and selective DPPI inhibitors using lead optimization technology

Antiangiogenic agents targeting VEGFR kinase designed at Novartis

MK-0431: a novel approach to type 2 diabetes

Potential new Alzheimer's therapeutic advances through the pipeline at Lilly

Novel series of Kv1.1 current disinactivators presented by Wyeth

Arena continues to advance product pipeline

Millennium presents new CCR8 antagonists for asthma and other disorders

Novel KCNQ channel openers discovered by ICAgen team

Gruenenthal claims agents for opioid receptor and/or 5-HT/norepinephrine uptake modulation

New caspase activators prepared and tested by Cytovia researchers

New triptolide derivatives and their use reported by Pharmagenesis researchers

Lundbeck patent covers novel KCNQ2 potassium channel openers

Merck KGaA describes 5-HT1A/5-HT4 ligands able to inhibit 5-HT reuptake

Crucell signs PER.C6 licensing agreement with Wyeth

XTL Biopharmaceuticals to enroll new patients in HepeX-C study

Verta receives grant for pilot HCV study of SCV-07

Enrollment completed in phase IIa study of MM-093

IND filing for Provecta

BioDelivery Sciences International closes Arius acquisition

NicOx and Pfizer team up for nitric oxide-donating compound development

Roche seeks European approval of Tarceva for NSCLC

New synthetic peroxide artemisinin analogue for malaria enters human clinical trials

Aphton seeks Canadian registration of Insegia in pancreatic cancer

Yamanouchi to roll out Vesicare in E.U.

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...